Frank Dittmer

USPTO Granted Patents = 11 (Patent Applications = 5)

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 10.2

ph-index = 3

Forward Citations = 20(Granted Patents)

Location History:

Duesseldorf, DE (2012 - 2018)
Düsseldorf, DE (2017 - 2024)

Company Filing History:

5 out of 378

Bayer Pharma Aktiengesellschaft

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

patents

4. 1 out of 53

Aicuris Gmbh + Co. Kg.

patents

Years Active: 2012-2024

Loading Chart...

11 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11866495 - Anti-CEACAM6 antibodies and uses thereof (2024-01-09),

2. 11773164 - Anti-CEACAM6 antibodies and uses thereof (2023-10-03),

3. 11046783 - Antibodies capable of binding to the coagulation factor XIa and uses thereof (2021-06-29),

4. 10584167 - Anti-CEACAM6 antibodies and uses thereof (2020-03-10),

5. 10221247 - Antibodies capable of binding to the coagulation factor XIa and uses thereof (2019-03-05),

6. 10144784 - Monoclonal antibodies against antithrombin beta (2018-12-04),

7. 10040866 - Nucleic acids and host cells expressing antibodies capable of binding to the coagulation factor XIa and uses thereof (2018-08-07),

8. 9908942 - Monoclonal antibodies against antithrombin β (2018-03-06),

9. 9783614 - Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof (2017-10-10),

10. 9593166 - Monoclonal antibodies against antithrombin β (2017-03-14),

11. 8314089 - Substituted pyrazolamides and their use (2012-11-20),

Title: The Innovative Mind of Frank Dittmer: A Leader in Cancer Therapy

Introduction

Frank Dittmer, based in Düsseldorf, Germany, is a prolific inventor known for his significant contributions to the field of biotechnology. With a remarkable portfolio of 11 patents, Dittmer has focused on advancing therapeutic approaches for cancer treatment and other disorders.

Latest Patents

Among his latest innovations, Dittmer has developed a series of patents concerning anti-CEACAM6 antibodies. These inventions provide recombinant antigen-binding regions and antibodies that specifically target human CEACAM6, a protein associated with various cancers. Importantly, these antibodies do not significantly cross-react with similar proteins, ensuring greater precision in therapeutic applications. The patents further outline methods for generating these antibodies, along with nucleic acid sequences, vectors, pharmaceutical compositions, and detailed kits including instructions for use, facilitating their practical implementation in medical settings.

Career Highlights

Over the course of his career, Frank Dittmer has played a key role in organizations such as Bayer Pharma Aktiengesellschaft and Bayer Healthcare LLC, where he contributed to groundbreaking projects and honed his expertise in pharmaceutical innovation. His work primarily focuses on therapeutic solutions aimed at addressing complex medical challenges.

Collaborations

Dittmer has collaborated with a talented team of professionals, including notable coworkers like Michael Strerath and Uwe Gritzan. These collaborations have fostered a shared commitment to scientific advancement, driving the development of innovative solutions in the biotech industry.

Conclusion

Frank Dittmer stands out as a key figure in the realm of biotechnology and cancer therapy. His numerous patents and dedication to research signify a profound impact on both the scientific community and the lives of patients battling cancer. As he continues to explore new frontiers in medicine, Dittmer's innovations are poised to lead to significant advancements in therapeutic modalities.

This text is generated by artificial intelligence and may not be accurate.